ArticlePsycho-oncology2026
Associations Between Neurobehavioral Symptoms During Breast Cancer Chemotherapy and Patient-Reported Cognitive Impairment 3 or More Years After Chemotherapy.
Article in Psycho-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cognitive profiles and predictors of cancer-related cognitive impairment in breast cancer survivors: integrating self-reported, neuropsychological, and process-based measures.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2026Article
- Efficacy of Cognitive Training for Treating Cancer-related Cognitive Impairment: Systematic Review and Meta-analysis by Cognitive Domain.Neuropsychology review · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMany patients with breast cancer report cognitive impairment for several years after treatment. The objective of this study was to describe associations between neurobehavioral symptoms experienced during chemotherapy for early-stage breast cancer and patient-reported cancer-related cognitive impairment (CRCI) ≥ 3 years post-chemotherapy.
methodsThis study is a secondary analysis of women with stage I-III breast cancer who had enrolled in clinical trials promoting self-directed walking during chemotherapy and were re-consented for a study focused on quality-of-life outcomes ≥ 3 years post-chemotherapy. Patient-reported CRCI was assessed using the FACT-Cog PCI (cut point for impairment < 54). Multivariable log-binomial regression models, adjusting for age, race, and education, examined associations between long-term CRCI and baseline demographic characteristics, cancer diagnosis and treatment, and patient-reported neurobehavioral symptoms during chemotherapy and at long-term follow-up.
resultsAmong 104 participants, 39% reported CRCI at long-term follow-up, on average 6 years post-chemotherapy [range: 2.9-8.8]. CRCI was more common among those reporting moderate or worse depressive (RR 1.75, 95% CI 1.11-2.75, p = 0.02), anxiety (RR 1.95, 95% CI 1.22-3.11, p = 0.005), or fatigue (RR 1.92, 95% CI 1.09-3.36, p = 0.02) symptoms during chemotherapy. In sensitivity analyses limited to patients with none or mild symptoms prior to chemotherapy, depressive (RR 2.11, 95% CI 1.23-3.63, p = 0.007) and fatigue (RR 1.81, 95% CI 1.81, 95% CI 1.01-3.24, p = 0.05) symptoms emerging during chemotherapy were also associated with CRCI at follow-up.
conclusionsPatient-reported neurobehavioral symptoms experienced during chemotherapy, including depression, anxiety, and fatigue, were associated with patient-reported CRCI years after primary treatment and should be monitored for timely intervention opportunities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.